ribavirin has been researched along with balapiravir in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Nelson, D; Nyberg, L; Pockros, P; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Kronenberger, B; Zeuzem, S | 1 |
1 review(s) available for ribavirin and balapiravir
| Article | Year |
|---|---|
Future treatment options for HCV: double, triple, what is the optimal combination?
Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin | 2008 |
1 trial(s) available for ribavirin and balapiravir
| Article | Year |
|---|---|
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
2 other study(ies) available for ribavirin and balapiravir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2008 |